Marseille

• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA … Recruiting
  2022-501866-22-00 9 2025-08-26 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting
  2022-502910-10-00 7 2025-08-11 Propionic Acidemia
• A Study of YL201 in Patients With Advanced Solid Tumors Recruiting
  2024-517589-41-00 1 2025-08-04 Advanced solid tumors
• A Phase 1, Open-Label Dose Escalation and Expansion study of SNV1521 in Participants with Advanced Solid Tumors Recruiting
  2025-520557-36-00 1 2025-07-24 Advanced Solid Tumors
• A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with … Recruiting
  2024-516616-24-00 5 2025-07-23 Acromegaly
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-10 … Recruiting
  2024-519128-26-00 4 2025-05-22 Non-foveal geographic atrophy secondary to non-neovascular age-related
• A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants … Recruiting
  2024-514239-21-00 3 2025-05-21 Spinal Muscular Atrophy
• A Study to Investigate ALE.P02 as Monotherapy in Adult Patients with Selected CLDN1+ Solid Tumors Recruiting
  2024-515459-39-00 7 2025-05-08 Advanced or Metastatic Squamous Solid Tumors
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the … Recruiting
  2024-511239-91-00 4 2025-05-05 Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• A Study to Assess Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Adult Participants with Metastatic Urothelial Carcino … Recruiting
  2024-515506-11-00 4 2025-03-24 Urothelial Carcinoma
• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 5 2025-02-24 Haemophilia A
• A trial to investigate teprotumumab mg/ml subcutaneous administration compared with placebo in male and female adult participants with moder … Recruiting
  2024-515702-63-00 5 2025-02-20 Moderate-to-Severe Active Thyroid Eye Disease
• A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting
  2024-516869-36-00 1 2025-02-17 Relapsed or refractory B-cell malignancies: chronic lymphocytic leukem
• TAR-0520 gel in EGFR inhibitor-induced folliculitis Recruiting
  2024-516339-28-00 4 2025-02-10 EGFR inhibitor-induced folliculitis
• A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Hematologic Maligna … Recruiting
  2024-511457-22-00 3 2025-01-30 Advanced Hematologic Malignancies
• A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma Recruiting
  2024-513077-48-00 5 2024-12-19 O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma

Showing 193–216 of 1,485 trials